NCT00959751View on ClinicalTrials.gov

Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2010

Conditions
Migraine Without Aura
Interventions
DRUG

NXN-188

200 mg capsules, 600 mg, PRN

DRUG

Placebo

200 mg capsules with no active ingredient designed to match the NXN-188 capsules

Trial Locations (4)

10550

Elkind Headache Center, Mount Vernon

30328

Comprehensive NeuroScience, Inc. Atlanta, Atlanta

33716

Comprehensive Neuroscience, Inc., St. Petersburg

84106

Lifetree Clinical Research, Salt Lake City

Sponsors

Lead Sponsor

NeurAxon Inc.
All Listed Sponsors
lead

NeurAxon Inc.

INDUSTRY